ストックスクリーナーアプリを入手
2.02
5.61%
-0.12
アフターアワーズ：
2.00
-0.02
-0.99%
前日終値:
$2.14
開ける：
$2.08
24時間の取引高:
73,274
Relative Volume:
1.43
時価総額：
$24.35M
収益：
$52.16M
当期純損益:
$-48.60M
株価収益率:
-2.2198
EPS:
-0.91
ネットキャッシュフロー:
$-77.48M
1週間 パフォーマンス:
-5.16%
1か月 パフォーマンス:
-25.74%
6か月 パフォーマンス:
-69.25%
1年 パフォーマンス:
-64.25%
1日の値動き範囲:
$2.00
$2.14
1週間の範囲:
$1.9601
$2.27
52週間の値動き範囲:
$1.88
$11.30
Hookipa Pharma Inc Stock (HOOK) Company Profile
名前
Hookipa Pharma Inc
セクター
電話
0114318906360
住所
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY
HOOK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HOOK
Hookipa Pharma Inc
|
2.02 | 24.35M | 52.16M | -48.60M | -77.48M | -4.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-15 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-12-02 | ダウングレード | BofA Securities | Buy → Underperform |
| 2021-11-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-08 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-03 | 開始されました | Truist | Buy |
| 2020-10-26 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-19 | 再開されました | H.C. Wainwright | Buy |
| 2019-09-27 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-13 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Hookipa Pharma Inc (HOOK) 最新ニュース
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26% - Simply Wall St
RBC downgrades HOOKIPA Pharma stock to Sector Perform as restructuring resets pipeline to preclinical - Investing.com
HOOKIPA Pharma's SWOT analysis: stock faces challenges amid pipeline shifts By Investing.com - Investing.com South Africa
Fmr LLC Has $1.47 Million Holdings in Hookipa Pharma Inc (NASDAQ:HOOK) - Defense World
HOOKIPA Pharma's SWOT analysis: stock faces challenges amid pipeline shifts - Investing.com
Hookipa Pharma stock hits 52-week low at $2.07 amid market challenges - Investing.com
HOOK (HOOKIPA Pharma) COGS-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com
HOOK (HOOKIPA Pharma) GF Value Rank : 2 (As of Nov. 25, 2024) - GuruFocus.com
HOOK (HOOKIPA Pharma) Debt-to-Equity : 0.04 (As of Sep. 2024) - GuruFocus.com
JMP Securities Has Lowered Expectations for Hookipa Pharma (NASDAQ:HOOK) Stock Price - Defense World
Hookipa Pharma price target lowered to $7 from $24 at JMP Securities - Yahoo Finance
Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program - Yahoo Finance
Hookipa Pharma stock hits 52-week low at $2.62 amid market challenges - Investing.com Canada
Hookipa Pharma stock hits 52-week low at $2.62 amid market challenges By Investing.com - Investing.com South Africa
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky - Simply Wall St
HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
HOOKIPA Pharma stock target lowered, maintains outlook on strategic direction - Investing.com
RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target - Quantisnow
HOOKIPA Pharma Inc (HOOK) Quarterly 10-Q Report - Quartzy
Hookipa Pharma stock hits 52-week low at $3.4 amid market challenges - Investing.com Australia
Hookipa Pharma Reports Q3 Earnings Amid Strategic Changes - TipRanks
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates - The Bakersfield Californian
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker - The Manila Times
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker - GlobeNewswire
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market By Investing.com - Investing.com UK
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 - Quantisnow
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline - GlobeNewswire
HOOKIPA commences HPV16+ cancer adjuvant care trial - Investing.com India
HOOKIPA commences HPV16+ cancer adjuvant care trial By Investing.com - Investing.com Nigeria
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer - The Manila Times
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator - The Bakersfield Californian
HOOKIPA Pharma Doses First Patients with Eseba-vec as - GlobeNewswire
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges By Investing.com - Investing.com South Africa
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges - Investing.com
Hookipa Pharma stock hits 52-week low at $4.06 amid market challenges - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in cancer immunotherapy - Investing.com
HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
HOOKIPA presents KRAS cancer treatment data By Investing.com - Investing.com South Africa
HOOKIPA presents KRAS cancer treatment data - Investing.com India
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset - Marketscreener.com
Hookipa Pharma Inc (HOOK) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):